Noventra Pharma Retatrutide (32mg Self-Mix – Triple GLP-1/GIP/Glucagon Agonist)

Retatrutide is an investigational peptide supplied in a lyophilized (self-mix) format, requiring reconstitution prior to use. It is investigated for its role in metabolic and endocrine signalling pathways through activity at glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors.

Retatrutide has been studied in experimental and clinical contexts for its interaction with pathways involved in energy balance, glucose regulation, and metabolic signalling processes.

Key Features:

• 32mg retatrutide per vial

• Triple receptor agonist: GLP-1, GIP, and glucagon receptor activity

• Lyophilized (self-mix) format requiring reconstitution

• Investigated for roles in metabolic and endocrine signalling pathways

• Studied in relation to energy balance and glucose regulation processes

• Associated in research with metabolic pathway modulation

Suggested Use:
For research or controlled clinical use only. Protocols vary depending on study design and should be determined by qualified professionals in an appropriate setting.

Storage:

• Unreconstituted (lyophilized): Store in a cool, dry place (15–25°C), protected from light. Refrigeration (2–8°C) may be used for extended stability

• After reconstitution: Store at 2–8°C. Do not freeze

• Avoid repeated freeze–thaw cycles

• Use within a limited timeframe once reconstituted (based on formulation stability)

Important Information:
Retatrutide is an investigational compound and is not approved for general use in many regions. It should be handled and used within appropriate research or clinical frameworks under qualified supervision. Not recommended for individuals under 18, pregnant or breastfeeding individuals, or those with certain medical conditions. Ensure compliance with applicable regulations prior to use.